Literature DB >> 2835908

Atypical retinitis in patients with the acquired immunodeficiency syndrome.

M T Fay1, W R Freeman, C A Wiley, D Hardy, S Bozzette.   

Abstract

We examined three patients with AIDS who had large, sharply demarcated areas of thinned retina consistent with inactive cytomegalovirus retinitis and who were not treated with ganciclovir. These lesions appeared identical to clinically inactive areas of cytomegalovirus retinitis after effective antiviral treatment. All patients were receiving azidothymidine or ribavirin, or both, which have activity against the human immunodeficiency virus and which may improve immune function. All patients also received oral acyclovir at doses ineffective against cytomegalovirus retinitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835908     DOI: 10.1016/0002-9394(88)90239-5

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Evidence for cytomegalovirus and human immunodeficiency virus infection of the retina in AIDS.

Authors:  A Schmitt-Gräff; E Neuen-Jacob; B Rettig; R Sundmacher
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.

Authors:  R D Schrier; W R Freeman; C A Wiley; J A McCutchan
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

3.  Role of antigenemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients.

Authors:  D Francisci; A Tosti; R Preziosi; F Baldelli; G Stagni; S Pauluzzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

4.  Relationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDS.

Authors:  Gary N Holland; Mark L Van Natta; David T Goldenberg; Rory Ritts; Ronald P Danis; Douglas A Jabs
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-05-01       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.